← Back to Patent Explorer
US4702909A Expired / Lapsed US ⏱️ 0.0 years remaining

Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent

Assignee: Louisiana State University
•
Filing: 1984-04-26
•
Granted: 1987-10-27
•
Expires: 2004-04-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Non-A, non-B hepatitis antigen, antigen compositions, vaccine and assay test for the detection of non-A, non-B hepatitis antigen. The antigen is characterized as having a particle size of about 2.0 nm to about 5.0 nm, a density of from about 1.24 to about 1.30 g/cm 3 , contains ribonucleic acid and occurs either free or bound to IgG molecules. The antigen can be isolated by isopycnic banding and chromatographic fractionation, and preferably by enzymatic digestion, isopycnic banding and chromatographic fractionation.

Inventors

  • 👤 Victor M. Villarejos
  • 👤 Kirsten A. Visona

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 05:24
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5767; A61K2039/51; A61K2039/525; A61K2039/5252; A61K2039/555; A61K2039/55505; C; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24234; Y; Y10; Y10S; Y10S436/00; Y10S436/82

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 36 words
A substantially purified non-A, non-B hepatitis antigen ATCC 40322, consisting essentially of particles having a size from about 2.0 to about 5.0 nm, and a density of from about 1.24 to about 1.30 g/cc in CsCl.
Claim 2
Dependent Claim 36 words
A substantially purified non-A, non-B hepatitis antigen ATCC 40322, consisting essentially of particles having a size from about 2.0 to about 5.0 nm, and a density of from about 1.24 to about 1.30 g/cc in CsCl.
Claim 3
Dependent Claim 19 words
The antigen according to claim 1 having a molecular weight of from about 200,000 daltons to about 300,000 daltons.
Claim 4
Dependent Claim 34 words
The antigen according to claim 1 which, when complexed with human lipoproteins of host origin , or human, immunoglobin G. has a molecular weight of from about 800,000 daltons to about 1,000,000 ol daltons.
Claim 5
Dependent Claim 21 words
A subunit antigenic component of the non-A, non-B hepatitis antigen of claim 1 having a molecular weight of about 50,000 daltons.
Claim 6
Dependent Claim 12 words
A composition comprising the antigen of claim 1 in an aqueous vehicle.
Claim 7
Dependent Claim 16 words
A composition according to claim 5 wherein the vehicle is water, saline or phosphate buffered saline.
Claim 8
Dependent Claim 9 words
The antigen according to claim 1 adsorbed on alum.
Claim 9
Dependent Claim 18 words
A vaccine comprising an immunologically effective amount of the antigen of claim 1 and a physiologically acceptable vehicle.
Claim 10
Dependent Claim 33 words
The antigen according to claim 1 further defined in that the sedimentation coefficient of the particles ranges from about 30 S to about 40 S (linear sucrose gradient), and it contains ribonucleic acid.
Claim 11
Dependent Claim 26 words
A diagnostic reagent comprising the antigen of claim 1 in an aqueous medium in a quantity effective to form an immune complex in a diagnostic assay.
Claim 12
Dependent Claim 54 words
A process for isolating a non-A, non-B hepatitis antigen ATCC 40322 , subjecting serum containing non-A, non-B hepatitis antigen, ATCC 40322, to isopycnic banding and selecting a fraction having a density equivalent to from about 1.24 to about 1.30 g/cc in CsC1, and a particle size of from about 2.0 to about 5.0 nm.
Claim 13
Dependent Claim 54 words
A process for isolating a non-A, non-B hepatitis antigen ATCC 40322 , subjecting serum containing non-A, non-B hepatitis antigen, ATCC 40322, to isopycnic banding and selecting a fraction having a density equivalent to from about 1.24 to about 1.30 g/cc in CsC1, and a particle size of from about 2.0 to about 5.0 nm.
Claim 14
Dependent Claim 27 words
A process according to claim 11 wherein the selected fraction is treated to separate particles having a molecular weight of from about 200,000 to about 300,000 daltons.
Claim 15
Dependent Claim 42 words
A process according to claim 11 wherein the selected fraction is treated to separate particles which, when complexed with human lipoproteins of host origin, or human immunoglobin G, have has a molecular weight of from about 800,000 daltons to about 1,000,000 daltons.
Claim 16
Dependent Claim 37 words
A process according to claim 11 wherein the treatment separates particles having a molecular weight of from about 200,000 to about 300,000 daltons, and particles having a molecular weight of from about 800,000 to about 1,000,000 daltons.
Claim 17
Dependent Claim 36 words
The process according to claim 11 wherein the antigen is further defined in that the sedimentation coefficient of the particles ranges from about 30 S to about 40 S (linear sucrose gradient), and contains ribonucleic acid.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-10-26 1991-04-27 1991-10-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-10-26 1995-04-27 1995-10-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-10-26 1999-04-27 1999-10-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag